Revance Therapeutics (NASDAQ:RVNC) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($1.24) EPS for the quarter, topping analysts' consensus estimates of ($1.25) by $0.01, MarketWatch Earnings reports. Revance Therapeutics had a negative return on equity of 85.72% and a negative net margin of 5,818.87%.
NASDAQ RVNC traded down $0.76 on Tuesday, reaching $26.20. The company had a trading volume of 608 shares, compared to its average volume of 425,713. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -5.86 and a beta of 1.42. Revance Therapeutics has a fifty-two week low of $11.78 and a fifty-two week high of $34.62. The business has a 50 day moving average of $28.31 and a two-hundred day moving average of $26.92. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.07 and a quick ratio of 7.01.
RVNC has been the topic of several recent analyst reports. Needham & Company LLC lifted their target price on Revance Therapeutics from $42.00 to $45.00 and gave the stock a "buy" rating in a report on Friday, January 8th. HC Wainwright reiterated a "buy" rating and set a $35.00 target price (up previously from $33.00) on shares of Revance Therapeutics in a report on Tuesday. Barclays boosted their price target on Revance Therapeutics from $35.00 to $38.00 and gave the stock an "overweight" rating in a research report on Monday, October 26th. Mizuho boosted their price target on Revance Therapeutics from $30.00 to $33.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, Zacks Investment Research downgraded Revance Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, February 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of "Buy" and a consensus target price of $32.88.
In related news, insider Aubrey Rankin sold 33,119 shares of the stock in a transaction on Monday, February 1st. The stock was sold at an average price of $25.95, for a total value of $859,438.05. Following the completion of the sale, the insider now directly owns 67,871 shares in the company, valued at $1,761,252.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.80% of the company's stock.
About Revance Therapeutics
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine.
Recommended Story: What are retained earnings?
7 Lithium Stocks That Will Power the Electric Vehicle Boom
Demand for lithium is set to increase exponentially in the next few years. In fact, according to Statista, demand for lithium may very well double to 820,000 tons in that time. Some of that demand will come from companies that are manufacturing the batteries that we use every day. For example, lithium is an essential component of the batteries that power our mobile devices.
But the real growth will come as the United States goes all-in on electric vehicles (EVs). The Biden administration recently announced plans to have the U.S. government’s fleet of over 600,000 vehicles converted to EVs.
And as you’re aware, EV stocks are in a bubble of some sort at the moment. Some of that is due to the increasing number of companies that went public last year. However, as investors are beginning to realize, not all of these companies will be the next Tesla. In fact, some of these companies may never be successful at bringing an EV to market, at least not at the scale that will be required.
The ones that do make it will need lithium and lots of it. To help you sift through the best lithium stocks to buy, we’ve put together this special presentation.
View the "7 Lithium Stocks That Will Power the Electric Vehicle Boom".
